์ค๋ฆฌ๋ง๋ฆฐ / ๋ฐํฌ์จ์ฌ
**์ค๋ฆฌ๋ง๋ฆฐ(Silymarin)**์ ๋ฐํฌ์จ์ฌ(*Silybum marianum*)์ ์จ์์์ ์ถ์ถํ ํ๋ผ๋ณด๋๋ฆฌ๊ทธ๋ ๋ณตํฉ์ฒด์ ๋๋ค. ์์ํ์์ **๊ฐ์ฅ ๋ณดํธ ๊ธฐ๋ฅ์ฑ ์์์ **๋ก ๋๋ฆฌ ์ฌ์ฉ๋ฉ๋๋ค. * **์ฃผ์ ์ฉ๋:** ๊ฐ, ๊ณ ์์ด ๋ฐ ๊ธฐํ ๋๋ฌผ์ ๊ธยท๋ง์ฑ ๊ฐ์งํ, ๊ฐ๊ฒฝ๋ณ ๋ฐ ์ผ์ฆ์ฑ ๊ฐ์งํ ๊ด๋ฆฌ. * **๋ ์ ํด๋ ์ :** ์๊ด๋๋ฒ์ฏ(*Amanita phalloides*)๊ณผ ๊ฐ์ ์ฌ๊ฐํ ๊ฐ๋ ์ฑ ๋ฌผ์ง ์ญ์ทจ ํ ๊ฐ ๋ณดํธ์ ๋ก ํนํ ์ค์ํ ์ญํ ์ ํฉ๋๋ค. * **์ข ์ํ์ ์ง์:** ์ต๊ทผ ์คํ ๋ฐ์ดํฐ์ ๋ฐ๋ฅด๋ฉด ํน์ ์์ ์๋ฐฉํ๊ณ ํน์ ํํ์๋ฒ์ ๊ฐ๋ ์ฑ ๋ถ์์ฉ์ ์ค์ด๋ ๋ฐ ๋์์ด ๋ ์ ์์ต๋๋ค. > **์์ ํ:** ์ค๋ฆฌ๋ง๋ฆฐ์ ๊ธฐ๋ฅ์ฑ ์์์ ์ด๋ฏ๋ก ์ผ๋ฐ ์์ฝํ์ ํ์ง๊ณผ ์์ฒด ์ด์ฉ๋ฅ ์ด ๋งค์ฐ ๋ค์ํฉ๋๋ค. ์ค๋ฆฌ๋น๋์ด ํฌ์คํํฐ๋์ฝ๋ฆฐ๊ณผ ๊ฒฐํฉ๋(ํ์ดํ ์ ๊ธฐ์ ) ์์๊ณผ ์ ์ฉ ์ ์ ๋ ์ผ๋ฐ ์ถ์ถ๋ฌผ์ ๋นํด ์์ฅ๊ด ํก์์จ์ด ํจ์ฌ ๋ฐ์ด๋๋ฏ๋ก ๊ฐ๋ ฅํ ๊ถ์ฅ๋ฉ๋๋ค.
์์ฉ ๊ธฐ์ : Silymarin exerts its hepatoprotective effects through multiple synergistic pathways. **Silibinin** (or silybin) is the most biologically active component of the complex. * **Antioxidant & Free Radical Scavenging:** Inhibits lipid peroxidase and beta-glucuronidase. It directly scavenges reactive oxygen species (ROS) and significantly increases intracellular **glutathione** levels in the liver. * **Membrane Stabilization:** Alters the outer hepatocyte cell membrane structure, competitively blocking the binding and transmembrane transport of hepatotoxins (e.g., amatoxins from poisonous mushrooms). * **Anti-inflammatory:** Inhibits the cytotoxic, inflammatory, and apoptotic effects of **Tumor Necrosis Factor-alpha (TNF-ฮฑ)** and modulates leukotriene synthesis. * **Antifibrotic:** Reduces hepatic stellate cell activation, thereby decreasing hepatic collagen formation and slowing the progression of cirrhosis. * **Regenerative:** Stimulates ribosomal RNA polymerase A โ enhances protein synthesis and accelerates hepatocyte regeneration.
๋๋ฌผ ์ข ๋ณ ์ฉ๋
- Therapeutic dosage (general) ยท 50-250 mg/day ยท PO ยท q24h ยท Suggested dose range
- Adjunctive therapy for chronic liver disease ยท 20-50 mg/kg per day ยท PO ยท q24h ยท Extrapolated from human, monkey, rodent and dog research
- Chronic liver disease and ameliorating the effects of anticonvulsants ยท 50-200 mg ยท PO ยท q12-24h
- Hepatotoxicity, hepatic recovery/regeneration, hepatic fibrosis ยท 20-50 mg/kg/day ยท PO ยท q24h
- General hepatic support ยท 4-8 mg/kg/day ยท PO ยท q24h
- Therapeutic dosage (general) ยท 50-250 mg/day ยท PO ยท q24h ยท Suggested dose range
- Adjunctive therapy for chronic liver disease ยท 20-50 mg/kg per day ยท PO ยท q24h ยท Extrapolated from human, monkey, rodent and dog research
- Chronic liver disease and ameliorating the effects of anticonvulsants ยท 50-200 mg ยท PO ยท q12-24h
- Hepatotoxicity, hepatic recovery/regeneration, hepatic fibrosis ยท 20-50 mg/kg/day ยท PO ยท q24h
์ฉ๋์ ๋ฉดํ ์์ ์ ๋ฌธ๊ฐ๋ฅผ ์ํ ์์ ์ฐธ๊ณ ์๋ฃ์ ๋๋ค. ํญ์ ์ต์ ๋ผ๋ฒจ๊ณผ ๊ฐ๋ณ ํ์์ ๋ํด ํ์ธํ์ญ์์ค.
ํฌ์ฌ ๊ฒฝ๋ก
๊ธ๊ธฐ
- Known hypersensitivity or allergy to the Asteraceae/Compositae plant family (ragweed, marigolds, daisies)
- Use caution with whole plant extracts (not the seed extract) in patients where exogenous estrogens are contraindicated, due to potential estrogen-like activity
์ด์๋ฐ์
- Gastrointestinal upset (mild nausea, vomiting, diarrhea)
- Allergic reactions in patients sensitive to the Asteraceae/Compositae plant family
- Generally very well tolerated
- Rare mild gastrointestinal upset
์ฝ๋ฌผ ์ํธ์์ฉ
- CYP2C9 Substrates (e.g., warfarin, amitriptyline, verapamil) ยท Silymarin may inhibit cytochrome P450 isoenzyme 2C9 (CYP2C9). Use caution with narrow therapeutic index drugs metabolized by this pathway.
- CYP3A4 Substrates ยท May inhibit CYP3A4, though clinical significance is currently undetermined.
- Drugs undergoing hepatic glucuronidation (acetaminophen, diazepam, morphine, lamotrigine) ยท Silymarin may increase the clearance of these drugs (not applicable in cats). Clinical significance is undetermined.
๋ชจ๋ํฐ๋ง
- Clinical efficacy (resolution of clinical signs)
- Liver enzyme panels (ALT, AST, ALP, GGT)
- Hepatic function tests (Bilirubin, Bile Acids, BUN, Albumin)
- Liver enzymes (ALT, AST, ALP, GGT)
- Total bilirubin
- Bile acids
- Clinical signs of hepatic disease (e.g., icterus, lethargy, appetite)
๊ณผ์ฉ๋
Overdoses are highly unlikely to cause significant morbidity due to the supplement's high safety margin. Mild gastrointestinal effects (vomiting, diarrhea) may be seen and should be treated in a supportive and symptomatic manner.
VetSheet ์ฝ๋ฌผ ๋ ํผ๋ฐ์ค๋ ๋ฉดํ ์์ ์ ๋ฌธ๊ฐ๋ฅผ ์ํ ์์ ์์ฌ๊ฒฐ์ ๋ณด์กฐ ๋๊ตฌ์ด๋ฉฐ, ์ ๋ฌธ์ ํ๋จ์ด๋ ์ ์กฐ์ฌ์ ์ต์ ๋ผ๋ฒจ์ ๋์ ํ์ง ์์ต๋๋ค.